Eisai and Biogen reported new real-world data for LEQEMBI in early Alzheimer’s: 82.5% of patients remained stable or improved after an average of 17 months of treatment. The update is a supportive real-world effectiveness signal for the therapy, which should be modestly positive for sentiment around the drug.
Eisai and Biogen reported new real-world data for LEQEMBI in early Alzheimer’s: 82.5% of patients remained stable or improved after an average of 17 months of treatment. The update is a supportive real-world effectiveness signal for the therapy, which should be modestly positive for sentiment around the drug.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
